These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 15523180

  • 1. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV, Vaziri I, Frisbee-Hume S, Streeter H, LeBlanc B.
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [Abstract] [Full Text] [Related]

  • 2. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 3. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [Abstract] [Full Text] [Related]

  • 6. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV, Yadegarynia D, Kontoyiannis DP, Raad II, Ho DH.
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 8. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [Abstract] [Full Text] [Related]

  • 9. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria.
    Bassetti M, Dembry LM, Farrel PA, Callan DA, Andriole VT.
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):143-8. PubMed ID: 11750168
    [Abstract] [Full Text] [Related]

  • 10. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 11. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
    Fedler KA, Jones RN, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [Abstract] [Full Text] [Related]

  • 13. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
    Reddy AK, Garg P, Alam MR, Gopinathan U, Sharma S, Krishnaiah S.
    Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
    [Abstract] [Full Text] [Related]

  • 14. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones.
    Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II.
    Diagn Microbiol Infect Dis; 2005 Mar; 51(3):215-8. PubMed ID: 15766609
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 16. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS.
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [Abstract] [Full Text] [Related]

  • 17. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 19. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R, Brenwald NP, Andrews JM, Boswell F.
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
    Iffat W, Shoaib MH, Muhammad IN, Rehana, Tasleem S, Gauhar S.
    Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.